potassiumvial size availability ndc 0409-7295-11 15 ml single-dose fliptop vial ndc 63323-0086-05...

6
NOW AVAILABLE The First FDA-Approved Potassium Phosphates Injectable FIRST FDA APPROVED! P HAR M A Exclusively from Potassium PHOSPHATES INJECTION PPH-00012 FDA Approved Low Price Lower Aluminum Consistent Supply See page 5 for Important Safety Information

Upload: others

Post on 16-Sep-2020

4 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: PotassiumVial Size Availability NDC 0409-7295-11 15 mL Single-dose Fliptop Vial NDC 63323-0086-05 5mL NDC 63323-0086-15 15mL NDC 63323-0086-50 50mL NDC 46287-024-15 15 mL single-dose

NOW AVAILABLE

The First FDA-ApprovedPotassium Phosphates Injectable

FIRST FDA APPROVED!FIRST FDA APPROVED!

P H A R M A

Exclusively from

P H A R M A

Exclusively from

Important Safety Information

INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source

of phosphorus:

– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of

age and older when oral or enteral replacement is not possible, insufficient or contraindicated.

– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age

and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or

contraindicated.

• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing

less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due

to the risk of aluminum toxicity.

CONTRAINDICATIONS– hyperkalemia

– hyperphosphatemia

– hypercalcemia or significant hypocalcemia

– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease

WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:

Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-

tinuous electrocardiographic (ECG) monitoring may be needed during infusion.

– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress

occur, stop the infusion and initiate a medical evaluation.

– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or

treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-

ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.

Continuous ECG monitoring may be needed during infusion.

– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-

tions during and following infusion.

– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.

– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor

serum magnesium concentrations during treatment.

– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central

catheter.

DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If

use cannot be avoided, closely monitor serum potassium concentrations.

DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.

– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/

mL).

– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.

– See full prescribing information for instructions on preparation and administration.

ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.

To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PotassiumPHOSPHATESI N J E C T I O N

PotassiumPHOSPHATESI N J E C T I O N

Please see Full Prescribing Information in pocket for additional safety information

PPH-00012

It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been

approved by the FDA.

Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions

to their patients.

It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from

unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing

a consistent supply of an FDA-approved formulation.

Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection

from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate

replacement providing lower aluminum levels than current formulations.

Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct

hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral

replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive

for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by

standard electrolyte or nutrient solutions.

CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact

CMP Pharma at 252-753-7111.

Why Potassium Phosphates Injection from CMP Pharma?

FDA Approved

Low Price

Lower Aluminum

Consistent Supply

Inside right (full spread) Inside right (2-panel spread) Outside frontOutside back

See page 5 for Important Safety Information

Page 2: PotassiumVial Size Availability NDC 0409-7295-11 15 mL Single-dose Fliptop Vial NDC 63323-0086-05 5mL NDC 63323-0086-15 15mL NDC 63323-0086-50 50mL NDC 46287-024-15 15 mL single-dose

NOW AVAILABLE

The First FDA-ApprovedPotassium Phosphates Injectable

FIRST FDA APPROVED!FIRST FDA APPROVED!

P H A R M A

Exclusively from

P H A R M A

Exclusively from

Important Safety Information

INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source

of phosphorus:

– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of

age and older when oral or enteral replacement is not possible, insufficient or contraindicated.

– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age

and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or

contraindicated.

• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing

less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due

to the risk of aluminum toxicity.

CONTRAINDICATIONS– hyperkalemia

– hyperphosphatemia

– hypercalcemia or significant hypocalcemia

– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease

WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:

Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-

tinuous electrocardiographic (ECG) monitoring may be needed during infusion.

– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress

occur, stop the infusion and initiate a medical evaluation.

– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or

treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-

ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.

Continuous ECG monitoring may be needed during infusion.

– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-

tions during and following infusion.

– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.

– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor

serum magnesium concentrations during treatment.

– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central

catheter.

DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If

use cannot be avoided, closely monitor serum potassium concentrations.

DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.

– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/

mL).

– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.

– See full prescribing information for instructions on preparation and administration.

ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.

To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PotassiumPHOSPHATESI N J E C T I O N

PotassiumPHOSPHATESI N J E C T I O N

Please see Full Prescribing Information in pocket for additional safety information

PPH-00001

It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been

approved by the FDA.

Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions

to their patients.

It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from

unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing

a consistent supply of an FDA-approved formulation.

Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection

from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate

replacement providing lower aluminum levels than current formulations.

Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct

hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral

replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive

for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by

standard electrolyte or nutrient solutions.

CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact

CMP Pharma at 252-753-7111.

Why Potassium Phosphates Injection from CMP Pharma?

FDA Approved

Low Price

Lower Aluminum

Consistent Supply

Inside right (full spread) Inside right (2-panel spread) Outside frontOutside back

See page 5 for Important Safety Information

Page 3: PotassiumVial Size Availability NDC 0409-7295-11 15 mL Single-dose Fliptop Vial NDC 63323-0086-05 5mL NDC 63323-0086-15 15mL NDC 63323-0086-50 50mL NDC 46287-024-15 15 mL single-dose

Aluminum Toxicity

Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impair-

ment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature,

and they require large amounts of calcium and phosphate solutions, which also contain aluminum.

Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day

of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and

bone toxicity. Tissue loading may occur at even lower rates of administration. This product contains no

more than 15,000 mcg/L of aluminum.

P H A R M A

Exclusively from

PotassiumPHOSPHATESI N J E C T I O N

CMP Potassium Phosphates Injection is now available from

national and regional wholesalers. For more information, contact

CMP Pharma at 252-753-7111.

Potassium Phosphates Injection, USP–Pfizer Hospira*

Potassium Phosphates Injection, USP–Fresenius Kabi*

Potassium Phosphates Injection–CMP Pharma

US Approval Status

Not FDA Approved Not FDA Approved FDA Approved

Dosage Forms and Strengths

POTASSIUM PHOSPHATES

Injection, USP

45 mM P (3 mM P/mL

Potassium 4.4 mEq K+/mL

POTASSIUM PHOSPHATES

INJECTION, USP

3 mmol Phosphorus/mL and

4.4 mmol Potassium/mL 4.4

mEq Potassium/mL

POTASSIUM PHOSPHATES

Injection

45 mM P (3 mM P/mL)

Potassium 4.7 mEq K+/mL

Indications and Usage

Potassium Phosphates

Injection, USP, 3 mM P/mL is

indicated as a source of

phosphorus, for addition to

large volume intravenous

fluids, to prevent or correct

hypophosphatemia in

patients with restricted or no

oral intake. It is also useful

as an additive for preparing

specific intravenous fluid

formulas when the needs of

the patient cannot be met by

standard electrolyte or nutrient

solutions. The concomitant

amount of potassium (K+ 4.4

mEq/mL) must be calculated

into total electrolyte dose of

such prepared solutions.

Potassium Phosphates

Injection, USP (3 mmol/mL), is

indicated as a source of

phosphate, for addition to

large volume intravenous fluids

to prevent or correct

hypophosphatemia in patients

with restricted or no oral

intake. It is also useful as an

additive for preparing specific

intravenous fluid formulas

when the needs of the patient

cannot be met by standard

electrolyte or nutrient

solutions.

POTASSIUM PHOSPHATES

INJECTION is a phosphorus

replacement product indicated

as a source of phosphorus in

intravenous fluids to correct

hypophosphatemia in adults

and pediatric patients 12 years

of age and older when oral

or enteral replacement is not

possible, insufficient or

contraindicated and for

parenteral nutrition in adults

weighing at least 45 kg and

pediatric patients 12 years of

age and older weighing at least

40 kg when oral or enteral

nutrition is not possible,

insufficient or contraindicated.

Vial Size Availability

NDC 0409-7295-11

15 mL Single-dose Fliptop Vial

NDC 63323-0086-05 5mL

NDC 63323-0086-15 15mL

NDC 63323-0086-50 50mL

NDC 46287-024-15

15 mL single-dose glass vial

Aluminum Toxicity

Contains no more than

31,000 mcg/L.

Contains no more than

32,800 mcg/L of aluminum.

This product contains no

more than 15,000 mcg/L of

aluminum.

Storage Store at 20 to 25°C

(68 to 77°F).

Store between 15 and 30°C. Store at 2°C to 8°C (36°F to

46°F); After dilution, the solu-

tion is stable for 48 hours

under refrigeration at 2°C to

8°C (36°F to 46°F) or at room

temperature from 20°C to

25°C (68°F to 77°F)

WAC Price 15 mL $14.57 5 mL $14.8115 mL $30.2850 mL $67.27

15 mL $13.10

* All trademarks mentioned herein are the exclusive property of their respective owners.

FDA Approved

Low Price

Lower Aluminum

Consistent Supply

short lip glues here

short lip glues here

Inside centerInside left

Pocket folds over to glue on this side

Inside pocket back

Inside pocket front

Insert 1Trim size: 8 x 5.25

Flat Size: TBD—

(Do Not Hold Die-line)

See page 5 for Important Safety Information

Page 4: PotassiumVial Size Availability NDC 0409-7295-11 15 mL Single-dose Fliptop Vial NDC 63323-0086-05 5mL NDC 63323-0086-15 15mL NDC 63323-0086-50 50mL NDC 46287-024-15 15 mL single-dose

Aluminum Toxicity

Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impair-

ment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature,

and they require large amounts of calcium and phosphate solutions, which also contain aluminum.

Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day

of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and

bone toxicity. Tissue loading may occur at even lower rates of administration. This product contains no

more than 15,000 mcg/L of aluminum.

P H A R M A

Exclusively from

PotassiumPHOSPHATESI N J E C T I O N

CMP Potassium Phosphates Injection is now available from

national and regional wholesalers. For more information, contact

CMP Pharma at 252-753-7111.

Potassium Phosphates Injection, USP–Pfizer Hospira*

Potassium Phosphates Injection, USP–Fresenius Kabi*

Potassium Phosphates Injection–CMP Pharma

US Approval Status

Not FDA Approved Not FDA Approved FDA Approved

Dosage Forms and Strengths

POTASSIUM PHOSPHATES

Injection, USP

45 mM P (3 mM P/mL

Potassium 4.4 mEq K+/mL

POTASSIUM PHOSPHATES

INJECTION, USP

3 mmol Phosphorus/mL and

4.4 mmol Potassium/mL 4.4

mEq Potassium/mL

POTASSIUM PHOSPHATES

Injection

45 mM P (3 mM P/mL)

Potassium 4.7 mEq K+/mL

Indications and Usage

Potassium Phosphates

Injection, USP, 3 mM P/mL is

indicated as a source of

phosphorus, for addition to

large volume intravenous

fluids, to prevent or correct

hypophosphatemia in

patients with restricted or no

oral intake. It is also useful

as an additive for preparing

specific intravenous fluid

formulas when the needs of

the patient cannot be met by

standard electrolyte or nutrient

solutions. The concomitant

amount of potassium (K+ 4.4

mEq/mL) must be calculated

into total electrolyte dose of

such prepared solutions.

Potassium Phosphates

Injection, USP (3 mmol/mL), is

indicated as a source of

phosphate, for addition to

large volume intravenous fluids

to prevent or correct

hypophosphatemia in patients

with restricted or no oral

intake. It is also useful as an

additive for preparing specific

intravenous fluid formulas

when the needs of the patient

cannot be met by standard

electrolyte or nutrient

solutions.

POTASSIUM PHOSPHATES

INJECTION is a phosphorus

replacement product indicated

as a source of phosphorus in

intravenous fluids to correct

hypophosphatemia in adults

and pediatric patients 12 years

of age and older when oral

or enteral replacement is not

possible, insufficient or

contraindicated and for

parenteral nutrition in adults

weighing at least 45 kg and

pediatric patients 12 years of

age and older weighing at least

40 kg when oral or enteral

nutrition is not possible,

insufficient or contraindicated.

Vial Size Availability

NDC 0409-7295-11

15 mL Single-dose Fliptop Vial

NDC 63323-0086-05 5mL

NDC 63323-0086-15 15mL

NDC 63323-0086-50 50mL

NDC 46287-024-15

15 mL single-dose glass vial

Aluminum Toxicity

Contains no more than

31,000 mcg/L.

Contains no more than

32,800 mcg/L of aluminum.

This product contains no

more than 15,000 mcg/L of

aluminum.

Storage Store at 20 to 25°C

(68 to 77°F).

Store between 15 and 30°C. Store at 2°C to 8°C (36°F to

46°F); After dilution, the solu-

tion is stable for 48 hours

under refrigeration at 2°C to

8°C (36°F to 46°F) or at room

temperature from 20°C to

25°C (68°F to 77°F)

WAC Price 15 mL $14.57 5 mL $14.8115 mL $30.2850 mL $67.27

15 mL $13.10

* All trademarks mentioned herein are the exclusive property of their respective owners.

FDA Approved

Low Price

Lower Aluminum

Consistent Supply

short lip glues here

short lip glues here

Inside centerInside left

Pocket folds over to glue on this side

Inside pocket back

Inside pocket front

Insert 1Trim size: 8 x 5.25

Flat Size: TBD—

(Do Not Hold Die-line)

See page 5 for Important Safety Information

Page 5: PotassiumVial Size Availability NDC 0409-7295-11 15 mL Single-dose Fliptop Vial NDC 63323-0086-05 5mL NDC 63323-0086-15 15mL NDC 63323-0086-50 50mL NDC 46287-024-15 15 mL single-dose

NOW AVAILABLE

The First FDA-ApprovedPotassium Phosphates Injectable

FIRST FDA APPROVED!FIRST FDA APPROVED!

P H A R M A

Exclusively from

P H A R M A

Exclusively from

Important Safety Information

INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source

of phosphorus:

– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of

age and older when oral or enteral replacement is not possible, insufficient or contraindicated.

– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age

and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or

contraindicated.

• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing

less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due

to the risk of aluminum toxicity.

CONTRAINDICATIONS– hyperkalemia

– hyperphosphatemia

– hypercalcemia or significant hypocalcemia

– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease

WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:

Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-

tinuous electrocardiographic (ECG) monitoring may be needed during infusion.

– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress

occur, stop the infusion and initiate a medical evaluation.

– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or

treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-

ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.

Continuous ECG monitoring may be needed during infusion.

– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-

tions during and following infusion.

– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.

– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor

serum magnesium concentrations during treatment.

– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central

catheter.

DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If

use cannot be avoided, closely monitor serum potassium concentrations.

DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.

– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/

mL).

– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.

– See full prescribing information for instructions on preparation and administration.

ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.

To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PotassiumPHOSPHATESI N J E C T I O N

PotassiumPHOSPHATESI N J E C T I O N

Please see Full Prescribing Information in pocket for additional safety information

PPH-00001

It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been

approved by the FDA.

Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions

to their patients.

It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from

unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing

a consistent supply of an FDA-approved formulation.

Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection

from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate

replacement providing lower aluminum levels than current formulations.

Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct

hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral

replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive

for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by

standard electrolyte or nutrient solutions.

CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact

CMP Pharma at 252-753-7111.

Why Potassium Phosphates Injection from CMP Pharma?

FDA Approved

Low Price

Lower Aluminum

Consistent Supply

Page 6: PotassiumVial Size Availability NDC 0409-7295-11 15 mL Single-dose Fliptop Vial NDC 63323-0086-05 5mL NDC 63323-0086-15 15mL NDC 63323-0086-50 50mL NDC 46287-024-15 15 mL single-dose

NOW AVAILABLE

The First FDA-ApprovedPotassium Phosphates Injectable

FIRST FDA APPROVED!FIRST FDA APPROVED!

P H A R M A

Exclusively from

P H A R M A

Exclusively from

Important Safety Information

INDICATIONS AND USAGEPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source

of phosphorus:

– in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of

age and older when oral or enteral replacement is not possible, insufficient or contraindicated.

– for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age

and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or

contraindicated.

• Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing

less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due

to the risk of aluminum toxicity.

CONTRAINDICATIONS– hyperkalemia

– hyperphosphatemia

– hypercalcemia or significant hypocalcemia

– severe renal impairment (eGFR less than 30 mL/min/1.73m2) and end stage renal disease

WARNINGS AND PRECAUTIONS– Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration:

Administer only after dilution or admixing; do not exceed the recommended infusion rate. Con-

tinuous electrocardiographic (ECG) monitoring may be needed during infusion.

– Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress

occur, stop the infusion and initiate a medical evaluation.

– Hyperkalemia: Increased risk in patients with renal impairment, severe adrenal insufficiency, or

treated with drugs that increase potassium. Patients with cardiac disease may be more suscepti-

ble. Do not exceed the maximum daily amount of potassium or the recommended infusion rate.

Continuous ECG monitoring may be needed during infusion.

– Hyperphosphatemia and Hypocalcemia: Monitor serum phosphorus and calcium concentra-

tions during and following infusion.

– Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.

– Hypomagnesemia: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor

serum magnesium concentrations during treatment.

– Vein Damage and Thrombosis: Infuse concentrated or hypertonic solutions through a central

catheter.

DRUG INTERACTIONSUse of Other Medications that Increase Potassium: Avoid use in patients receiving such products. If

use cannot be avoided, closely monitor serum potassium concentrations.

DOSAGE AND ADMINISTRATION– Administer intravenously only after dilution or admixing in a larger volume of fluid.

– POTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/

mL).

– Monitor serum phosphorus, potassium, calcium, and magnesium concentrations.

– See full prescribing information for instructions on preparation and administration.

ADVERSE REACTIONSAdverse reactions are hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia.

To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PotassiumPHOSPHATESI N J E C T I O N

PotassiumPHOSPHATESI N J E C T I O N

Please see Full Prescribing Information in pocket for additional safety information

PPH-00001

It’s the first FDA-approved formulation available Currently, there is no other potassium phosphates injections formulation available that has been

approved by the FDA.

Market friendly price Competitively priced to ensure physicians have the choice to prescribe cost effective solutions

to their patients.

It addresses concerns from previous shortages of potassium phosphatesThe current phosphate repletion treatment market is strained due to previous shortages from

unapproved versions. Potassium Phosphates Injection helps alleviate these shortages by providing

a consistent supply of an FDA-approved formulation.

Current formulations have high aluminum contentCurrent unapproved formulations have higher aluminum content. Potassium Phosphates Injection

from CMP Pharma is a safe and consistent choice for healthcare professionals working with phosphate

replacement providing lower aluminum levels than current formulations.

Potassium Phosphates Injection is indicated as a source of phosphorus in intravenous fluids to correct

hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral

replacement is not possible, insufficient or contraindicated. Additionally, it is indicated as an additive

for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by

standard electrolyte or nutrient solutions.

CMP Potassium Phosphates Injection is now availablefrom national and regional wholesalers. For more information, contact

CMP Pharma at 252-753-7111.

Why Potassium Phosphates Injection from CMP Pharma?

FDA Approved

Low Price

Lower Aluminum

Consistent Supply

Inside right (full spread) Inside right (2-panel spread) Outside frontOutside back